These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 29680736

  • 1. Computational approach for generating robust models for discovering novel molecules as Cyclin Dependent Kinase 4 inhibitors.
    Divya V, Pushpa VL, Sarithamol S, Manoj KB.
    J Mol Graph Model; 2018 Jun; 82():48-58. PubMed ID: 29680736
    [Abstract] [Full Text] [Related]

  • 2. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA, Chen JJ, Qian HY, Pan YL, Chen JZ.
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [Abstract] [Full Text] [Related]

  • 3. Molecular docking and MD simulation studies of 4-thiazol-N-(pyridin-2-yl)pyrimidin-2-amine derivatives as novel inhibitors targeted to CDK2/4/6.
    Liang JD, Zhang YE, Qin F, Chen WN, Jiang WM, Fang Z, Liang XL, Zhang Q, Li J.
    J Cancer Res Clin Oncol; 2024 Jun 10; 150(6):302. PubMed ID: 38856753
    [Abstract] [Full Text] [Related]

  • 4. An in silico approach to discover the best molecular modeling strategy for designing novel CDK4 inhibitors.
    Vasanthakumari D, Vadakkethil Lalithabhai P, Kanthimathi Bahuleyan M.
    Chem Biol Drug Des; 2019 Apr 10; 93(4):556-569. PubMed ID: 30536727
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Insight into the interactions between novel isoquinolin-1,3-dione derivatives and cyclin-dependent kinase 4 combining QSAR and molecular docking.
    Zheng J, Kong H, Wilson JM, Guo J, Chang Y, Yang M, Xiao G, Sun P.
    PLoS One; 2014 Apr 10; 9(4):e93704. PubMed ID: 24722522
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Selective ATP competitive leads of CDK4: Discovery by 3D-QSAR pharmacophore mapping and molecular docking approach.
    Rondla R, PadmaRao LS, Ramatenki V, Haredi-Abdel-Monsef A, Potlapally SR, Vuruputuri U.
    Comput Biol Chem; 2017 Dec 10; 71():224-229. PubMed ID: 29153893
    [Abstract] [Full Text] [Related]

  • 10. Effect of hydrophobic and hydrogen bonding interactions on the potency of ß-alanine analogs of G-protein coupled glucagon receptor inhibitors.
    Venugopal PP, Das BK, Soorya E, Chakraborty D.
    Proteins; 2020 Feb 10; 88(2):327-344. PubMed ID: 31443129
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
    Zhang G, Ren Y.
    Molecules; 2018 Nov 09; 23(11):. PubMed ID: 30423939
    [Abstract] [Full Text] [Related]

  • 17. Structure-based and multiple potential three-dimensional quantitative structure-activity relationship (SB-MP-3D-QSAR) for inhibitor design.
    Du QS, Gao J, Wei YT, Du LQ, Wang SQ, Huang RB.
    J Chem Inf Model; 2012 Apr 23; 52(4):996-1004. PubMed ID: 22480344
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.